205
Participants
Start Date
June 30, 2016
Primary Completion Date
January 31, 2025
Study Completion Date
August 31, 2027
Procedure/Surgery
"Procedure/Surgery: Newly obtained biopsy if applicable and Blood samples collection.~For each patient:~* Frozen and paraffin embedded tumor material (archival or new biopsy) will be obtained for genetic profiling~* Blood samples will be obtained for genetic profiling and assessment of markers.~The classification as CINSARC will be performed for each patient. Patients should be treated by neoadjuvant anthracycline-based chemotherapy. Chemotherapy regimen must contain at least doxorubicin (dose range: 60 -75 mg/m²) and ifosfamide (dose range: 2.5-3g/m²) to be delivered on a 21-days cycle basis up to 6 cycles prior surgery. After neoadjuvant chemotherapy completion, patients will be treated by surgery followed or not by radiotherapy.~All patients should be managed according to the usual medical practices."
RECRUITING
Institut Paoli Calmettes, Marseille
RECRUITING
AP-HM _ Hôpital de la Timone, Marseille
RECRUITING
Centre Georges François Leclerc, Dijon
RECRUITING
Institut Claudius Regaud - IUCT-0, Toulouse
RECRUITING
Institut Bergonié, Bordeaux
RECRUITING
Institut de Cancérologie de l'Ouest, Nantes
NOT_YET_RECRUITING
Centre Oscar Lambret, Lille
RECRUITING
Centre Léon Bérard, Lyon
NOT_YET_RECRUITING
Institut Curie, Paris
NOT_YET_RECRUITING
Institut Gustave Roussy, Villejuif
Lead Sponsor
National Cancer Institute, France
OTHER_GOV
Ministry of Health, France
OTHER_GOV
Institut Bergonié
OTHER